Am J Perinatol 2016; 33(13): 1236-1241
DOI: 10.1055/s-0036-1584273
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Potential Role for Myoinositol in the Prevention of Gestational Diabetes Mellitus

Erika F. Werner
1   Department of Obstetrics and Gynecology, Alpert Medical School of Brown University, Providence, Rhode Island
,
Rosemary J. Froehlich
1   Department of Obstetrics and Gynecology, Alpert Medical School of Brown University, Providence, Rhode Island
› Author Affiliations
Further Information

Publication History

01 March 2016

27 April 2016

Publication Date:
23 May 2016 (online)

Abstract

More than 9% of overweight and obese women develop gestational diabetes mellitus (GDM) during pregnancy. Myoinositol is a promising supplement that may represent the first GDM-risk modifier that could be implemented on a population-level. It has been shown in animal and small human trials to prevent GDM through its insulin-mimetic properties. In animal studies, it also appears to decrease intra-abdominal adiposity and protect against diabetic embryopathies. In humans, four small randomized trials have demonstrated that myoinositol supplementation can lead to more than a 50% rate reduction in GDM compared with placebo. We now need a large, multicentered randomized controlled trial to demonstrate whether myoinositol has not only the promised impact on GDM rates, but also an effect on important secondary outcomes intricately linked to GDM, such as birth weight and neonatal intensive care unit admission.

 
  • References

  • 1 Kim SY, Saraiva C, Curtis M, Wilson HG, Troyan J, Sharma AJ. Fraction of gestational diabetes mellitus attributable to overweight and obesity by race/ethnicity, California, 2007-2009. Am J Public Health 2013; 103 (10) e65-e72
  • 2 Kim SY, Sharma AJ, Sappenfield W, Wilson HG, Salihu HM. Association of maternal body mass index, excessive weight gain, and gestational diabetes mellitus with large-for-gestational-age births. Obstet Gynecol 2014; 123 (4) 737-744
  • 3 Lawrence JM, Contreras R, Chen W, Sacks DA. Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999-2005. Diabetes Care 2008; 31 (5) 899-904
  • 4 Ferrara A, Kahn HS, Quesenberry CP, Riley C, Hedderson MM. An increase in the incidence of gestational diabetes mellitus: Northern California, 1991-2000. Obstet Gynecol 2004; 103 (3) 526-533
  • 5 Ovesen P, Rasmussen S, Kesmodel U. Effect of prepregnancy maternal overweight and obesity on pregnancy outcome. Obstet Gynecol 2011; 118 (2 Pt 1) 305-312
  • 6 Rosenberg TJ, Garbers S, Lipkind H, Chiasson MA. Maternal obesity and diabetes as risk factors for adverse pregnancy outcomes: differences among 4 racial/ethnic groups. Am J Public Health 2005; 95 (9) 1545-1551
  • 7 Giang L, Gjelsvik A, Cain R, Paine V. Gestational diabetes in Rhode Island. R I Med J (2013) 2013; 96 (4) 45-48
  • 8 Grobman WA, Bailit JL, Rice MM , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Can differences in obstetric outcomes be explained by differences in the care provided? The MFMU Network APEX study. Am J Obstet Gynecol 2014; 211 (2) 147.e1-147.e16
  • 9 Landon MB, Mele L, Spong CY , et al; Eunice Kennedy Shriver National Institute of Child Health, and Human Development (NICHD) Maternal–Fetal Medicine Units (MFMU) Network. The relationship between maternal glycemia and perinatal outcome. Obstet Gynecol 2011; 117 (2 Pt 1) 218-224
  • 10 Bodmer-Roy S, Morin L, Cousineau J, Rey E. Pregnancy outcomes in women with and without gestational diabetes mellitus according to the International Association of the Diabetes and Pregnancy Study Groups criteria. Obstet Gynecol 2012; 120 (4) 746-752
  • 11 Baptiste-Roberts K, Nicholson WK, Wang NY, Brancati FL. Gestational diabetes and subsequent growth patterns of offspring: the National Collaborative Perinatal Project. Matern Child Health J 2012; 16 (1) 125-132
  • 12 Chen Y, Quick WW, Yang W , et al. Cost of gestational diabetes mellitus in the United States in 2007. Popul Health Manag 2009; 12 (3) 165-174
  • 13 Shirazian T, Raghavan S. Obesity and pregnancy: implications and management strategies for providers. Mt Sinai J Med 2009; 76 (6) 539-545
  • 14 Moses RG, Luebcke M, Davis WS , et al. Effect of a low-glycemic-index diet during pregnancy on obstetric outcomes. Am J Clin Nutr 2006; 84 (4) 807-812
  • 15 Han S, Middleton P, Crowther CA. Exercise for pregnant women for preventing gestational diabetes mellitus. Cochrane Database Syst Rev 2012; 7: CD009021
  • 16 Tieu J, Crowther CA, Middleton P. Dietary advice in pregnancy for preventing gestational diabetes mellitus. Cochrane Database Syst Rev 2008; (2) CD006674
  • 17 Gould Rothberg BE, Magriples U, Kershaw TS, Rising SS, Ickovics JR. Gestational weight gain and subsequent postpartum weight loss among young, low-income, ethnic minority women. Am J Obstet Gynecol 2011; 204 (1) 52.e1-52.e11
  • 18 Hayes DK, Fan AZ, Smith RA, Bombard JM. Trends in selected chronic conditions and behavioral risk factors among women of reproductive age, behavioral risk factor surveillance system, 2001-2009. Prev Chronic Dis 2011; 8 (6) A120
  • 19 Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie 2013; 95 (10) 1811-1827
  • 20 Croze ML, Vella RE, Pillon NJ , et al. Chronic treatment with myo-inositol reduces white adipose tissue accretion and improves insulin sensitivity in female mice. J Nutr Biochem 2013; 24 (2) 457-466
  • 21 Artini PG, Di Berardino OM, Papini F , et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol 2013; 29 (4) 375-379
  • 22 Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol 2012; 28 (7) 509-515
  • 23 Malvasi A, Casciaro F, Minervini MM , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. Eur Rev Med Pharmacol Sci 2014; 18 (2) 270-274
  • 24 Corrado F, D'Anna R, Di Vieste G , et al. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med 2011; 28 (8) 972-975
  • 25 cioscia M, Kunjara S, Gumaa K , et al. Altered urinary release of inositol phosphoglycan A-type in women with gestational diabetes mellitus. Gynecol Obstet Invest 2007; 64 (4) 217-223
  • 26 Matarrelli B, Vitacolonna E, D'Angelo M , et al. Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. J Matern Fetal Neonatal Med 2013; 26 (10) 967-972
  • 27 D'Anna R, Scilipoti A, Giordano D , et al. myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care 2013; 36 (4) 854-857
  • 28 DʼAnna R, Di Benedetto A, Scilipoti A , et al. Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial. Obstet Gynecol 2015; 126 (2) 310-315
  • 29 Santamaria A, Di Benedetto A, Petrella E , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. J Matern Fetal Neonatal Med 2016; 29 (19) 3234-3237
  • 30 Crawford TJ, Crowther CA, Alsweiler J, Brown J. Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes. Cochrane Database Syst Rev 2015; 12: CD011507
  • 31 Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999; 340 (17) 1314-1320
  • 32 Iuorno MJ, Jakubowicz DJ, Baillargeon JP , et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002; 8 (6) 417-423
  • 33 D'Anna R, Di Benedetto V, Rizzo P , et al. Myo-inositol may prevent gestational diabetes in PCOS women. Gynecol Endocrinol 2012; 28 (6) 440-442
  • 34 Quirk Jr JG, Baumgarten B, Bleasdale JE. Effect of myo-inositol on the glycerophospholipid composition of adult and fetal rat lung tissue. J Perinat Med 1984; 12 (4) 201-210
  • 35 Bourbon JR, Doucet E, Rieutort M, Pignol B, Tordet C. Role of myo-inositol in impairment of fetal lung phosphatidylglycerol biosynthesis in the diabetic pregnancy: physiological consequences of a phosphatidylglycerol-deficient surfactant in the newborn rat. Exp Lung Res 1986; 11 (3) 195-207
  • 36 Anceschi MM, Petrelli A, Zaccardo G , et al. Inositol and glucocorticoid in the development of lung stability in male and female rabbit fetuses. Pediatr Res 1988; 24 (5) 617-621
  • 37 Guarner V, Tordet C, Bourbon JR. Effects of maternal protein-calorie malnutrition on the phospholipid composition of surfactant isolated from fetal and neonatal rat lungs. Compensation by inositol and lipid supplementation. Pediatr Res 1992; 31 (6) 629-635
  • 38 Hallman M, Bry K, Hoppu K, Lappi M, Pohjavuori M. Inositol supplementation in premature infants with respiratory distress syndrome. N Engl J Med 1992; 326 (19) 1233-1239